Evidence from a pooled analysis of the DAPA-HF and DELIVER trials has demonstrated that SGLT2 inhibitors provide a significant risk reduction for adverse outcomes, regardless of the presence of VCD [28]. This evidence concerns the gene SLC5A2 and hydrops fetalis.